FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4319462015> ?p ?o ?g. }

• W4319462015 endingPage "e2255050" @default.
• W4319462015 startingPage "e2255050" @default.
• W4319462015 abstract "Importance Use of tyrosine kinase inhibitors (TKIs) is the standard therapy for epidermal growth factor receptor ( EGFR )–mutated non–small cell lung cancer (NSCLC) with brain metastases. Several studies have shown that adding chemotherapy to EGFR-TKIs could improve progression-free survival (PFS) in patients with EGFR -mutant advanced NSCLC; however, the efficacy of these agents in patients with brain metastases remains unclear. Objective To investigate the efficacy and safety of gefitinib plus chemotherapy (pemetrexed with platinum) compared with gefitinib alone in patients with untreated EGFR- mutant NSCLC brain metastases. Design, Setting, and Participants This open-label prospective, multicenter, phase 3 randomized clinical trial was conducted in 6 centers in China from January 13, 2016, to August 27, 2021. The median follow-up time was 21.1 months (IQR, 13.5-31.8 months). Patients with untreated confirmed brain metastases and EGFR -sensitive mutated NSCLC were enrolled. Interventions The eligible patients were randomly assigned (1:1) to receive gefitinib plus chemotherapy or gefitinib alone. Main Outcomes and Measures The primary end point was intracranial PFS; secondary end points included PFS, overall survival (OS), intracranial objective response rate, overall objective response rate, and safety. Intention-to-treat analysis was performed. Results A total of 161 patients (87 [54.0%] women; mean [SD] age, 55 [9.8] years; range, 26-80 years) were enrolled and randomized to receive gefitinib (n = 81) or gefitinib plus chemotherapy (n = 80). The median intracranial PFS was 15.6 months (95% CI, 14.3-16.9 months) in the gefitinib plus chemotherapy group vs 9.1 months (95% CI, 8.0-10.2 months) in the gefitinib group (hazard ratio, 0.36; 95% CI, 0.25-0.53; P &amp;lt; .001). Similarly, the median PFS was significantly longer with gefitinib plus chemotherapy than gefitinib alone (16.3; 95% CI, 14.4-18.2 months vs 9.5; 95% CI, 8.3-10.8 months; P &amp;lt; .001). Gefitinib plus chemotherapy had a better intracranial objective response rate (85.0%; 95% CI, 77.0%-93.0% vs 63.0%; 95% CI, 52.2%-73.7%; P = .002) and overall objective response rate (80.0%; 95% CI, 71.0%-89.0% vs 64.2%; 95% CI, 53.5%-74.9%; P = .03) than gefitinib alone. At data cutoff, the median OS was also significantly longer in the gefitinib plus chemotherapy group vs the gefitinib group (35.0 vs 28.9 months; hazard ratio, 0.65; 95% CI, 0.43-0.99; P = .04). Grade 3 or worse adverse events were more common with gefitinib plus chemotherapy, most of which were manageable. Conclusions and Relevance In this randomized clinical trial, gefitinib plus chemotherapy significantly improved intracranial PFS, PFS, and OS compared with gefitinib alone in patients with untreated EGFR- mutant NSCLC brain metastases and could be an optional first-line treatment for these patients. Trial Registration ClinicalTrials.gov Identifier: NCT01951469" @default.
• W4319462015 created "2023-02-09" @default.
• W4319462015 creator A5003805532 @default.
• W4319462015 creator A5007362114 @default.
• W4319462015 creator A5016572253 @default.
• W4319462015 creator A5017941291 @default.
• W4319462015 creator A5027373861 @default.
• W4319462015 creator A5043852127 @default.
• W4319462015 creator A5048379858 @default.
• W4319462015 creator A5049834834 @default.
• W4319462015 creator A5056651386 @default.
• W4319462015 creator A5067131328 @default.
• W4319462015 creator A5079300884 @default.
• W4319462015 creator A5084453812 @default.
• W4319462015 date "2023-02-08" @default.
• W4319462015 modified "2023-10-16" @default.
• W4319462015 title "Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated <i>EGFR</i>-Mutant Non–Small Cell Lung Cancer in Patients With Brain Metastases" @default.
• W4319462015 cites W1978350956 @default.
• W4319462015 cites W2012295597 @default.
• W4319462015 cites W2019607817 @default.
• W4319462015 cites W2028315898 @default.
• W4319462015 cites W2040561412 @default.
• W4319462015 cites W2041835001 @default.
• W4319462015 cites W2091100650 @default.
• W4319462015 cites W2124967121 @default.
• W4319462015 cites W2127101185 @default.
• W4319462015 cites W2132157071 @default.
• W4319462015 cites W2153979476 @default.
• W4319462015 cites W2154803909 @default.
• W4319462015 cites W2160982674 @default.
• W4319462015 cites W2162724777 @default.
• W4319462015 cites W2268267848 @default.
• W4319462015 cites W2325642881 @default.
• W4319462015 cites W2397460919 @default.
• W4319462015 cites W2518488558 @default.
• W4319462015 cites W2520388920 @default.
• W4319462015 cites W2534288116 @default.
• W4319462015 cites W2581511343 @default.
• W4319462015 cites W2739010860 @default.
• W4319462015 cites W2770828094 @default.
• W4319462015 cites W2794883050 @default.
• W4319462015 cites W2888877308 @default.
• W4319462015 cites W2898978171 @default.
• W4319462015 cites W2937223370 @default.
• W4319462015 cites W2967398721 @default.
• W4319462015 cites W2979473538 @default.
• W4319462015 cites W2987053327 @default.
• W4319462015 cites W2990041408 @default.
• W4319462015 cites W3128870202 @default.
• W4319462015 cites W3165543715 @default.
• W4319462015 cites W4220855807 @default.
• W4319462015 cites W4220879423 @default.
• W4319462015 cites W4249030701 @default.
• W4319462015 cites W4292528167 @default.
• W4319462015 doi "https://doi.org/10.1001/jamanetworkopen.2022.55050" @default.
• W4319462015 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36753281" @default.
• W4319462015 hasPublicationYear "2023" @default.
• W4319462015 type Work @default.
• W4319462015 citedByCount "1" @default.
• W4319462015 countsByYear W43194620152023 @default.
• W4319462015 crossrefType "journal-article" @default.
• W4319462015 hasAuthorship W4319462015A5003805532 @default.
• W4319462015 hasAuthorship W4319462015A5007362114 @default.
• W4319462015 hasAuthorship W4319462015A5016572253 @default.
• W4319462015 hasAuthorship W4319462015A5017941291 @default.
• W4319462015 hasAuthorship W4319462015A5027373861 @default.
• W4319462015 hasAuthorship W4319462015A5043852127 @default.
• W4319462015 hasAuthorship W4319462015A5048379858 @default.
• W4319462015 hasAuthorship W4319462015A5049834834 @default.
• W4319462015 hasAuthorship W4319462015A5056651386 @default.
• W4319462015 hasAuthorship W4319462015A5067131328 @default.
• W4319462015 hasAuthorship W4319462015A5079300884 @default.
• W4319462015 hasAuthorship W4319462015A5084453812 @default.
• W4319462015 hasBestOaLocation W43194620151 @default.
• W4319462015 hasConcept C121608353 @default.
• W4319462015 hasConcept C126322002 @default.
• W4319462015 hasConcept C143998085 @default.
• W4319462015 hasConcept C168563851 @default.
• W4319462015 hasConcept C203092338 @default.
• W4319462015 hasConcept C2776256026 @default.
• W4319462015 hasConcept C2776694085 @default.
• W4319462015 hasConcept C2776907518 @default.
• W4319462015 hasConcept C2777240266 @default.
• W4319462015 hasConcept C2778239845 @default.
• W4319462015 hasConcept C2779438470 @default.
• W4319462015 hasConcept C2780580887 @default.
• W4319462015 hasConcept C71924100 @default.
• W4319462015 hasConceptScore W4319462015C121608353 @default.
• W4319462015 hasConceptScore W4319462015C126322002 @default.
• W4319462015 hasConceptScore W4319462015C143998085 @default.
• W4319462015 hasConceptScore W4319462015C168563851 @default.
• W4319462015 hasConceptScore W4319462015C203092338 @default.
• W4319462015 hasConceptScore W4319462015C2776256026 @default.
• W4319462015 hasConceptScore W4319462015C2776694085 @default.
• W4319462015 hasConceptScore W4319462015C2776907518 @default.
• W4319462015 hasConceptScore W4319462015C2777240266 @default.
• W4319462015 hasConceptScore W4319462015C2778239845 @default.
• W4319462015 hasConceptScore W4319462015C2779438470 @default.

• next